Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ (The Korean Society Nonclinical Study)-KSNS

ÇмúÇà»ç

·Î±×ÀÎ ¾ÆÀ̵ð ±â¾ï
 
ÇмúÇà»ç¸ñ·Ï Home > ÇмúÇà»ç > ÇмúÇà»ç¸ñ·Ï
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop °³ÃÖ ¾È³»
ÀÛ¼ºÀÚ °ü¸®ÀÚ email http://www.nonclinical.or.kr
Date2019³â 09¿ù 09ÀÏ 18:41Hits9866
÷ºÎÆÄÀÏ Files(399 kb) [°ø¹®] KSNS 36Â÷ ¿öÅ©¼¥ °³ÃÖ ¾È³»
Files(552 kb) Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop ÃÊ´ëÀå
Files(2424 kb) Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop - ±â¾÷È«º¸¸®Çø´
Files(20 kb) Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ ±â¼úºñÁî´Ï½º Çù·Â °øµ¿ ½ÉÆ÷Áö¿ò °èȹ¾È

Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop °³ÃÖ
"ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ"
2019³â 10¿ù 24ÀÏ(¸ñ) ~ 25ÀÏ(±Ý) / Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F)



1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀü°ú ±ÍÇÏÀÇ °Ç½ÂÇϽÉÀ» ±â¿øÇÕ´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼­´Â Á¦36Â÷ ¿öÅ©¼¥À» ¡°ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ"À̶ó´Â ÁÖÁ¦·Î ´ÙÀ½°ú °°ÀÌ °³ÃÖÇÏ¿À´Ï, ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù.


¡á Çà»ç°³¿ä

Çà»ç¸í Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦36Â÷ Workshop
ÁÖÁ¦ ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ
ÀϽà 2019³â 10¿ù 24ÀÏ(¸ñ) 12:00 ~ 25ÀÏ(±Ý) 15:00
Àå¼Ò Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F) ÀÚ¼¼È÷ º¸±â
ÁÖ¼Ò : Á¦ÁÖÆ¯º°ÀÚÄ¡µµ ¼­±ÍÆ÷½Ã ¼º»êÀ¾ ¼·ÁöÄÚÁö·Î 107 Èִнº Á¦ÁÖ
»çÀüµî·Ï 2019³â 9¿ù 10ÀÏ (È­) ~ 10¿ù 16ÀÏ (¼ö)
»çÀüµî·Ï±â°£ 2019³â 9¿ù 10ÀÏ (È­) ~ 10¿ù 16ÀÏ (¼ö)
1) ȨÆäÀÌÁö (www.nonclinical.or.kr)³» Á¦36Â÷ ¿öÅ©¼¥ »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
2) ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ µî·Ï °¡´É
µî·Ïºñ »çÀüµî·Ï 15¸¸¿ø(Çлý 10¸¸¿ø), ÇöÀåµî·Ï 15¸¸¿ø(¼÷¹Ú Á¦°ø ºÒ°¡)
1) »çÀüµî·Ï ¹× ÇöÀåµî·Ï Ä«µå°áÁ¦ °¡´É (Ä«µå°áÁ¦ ½Ã ¼¼±Ý°è»ê¼­ ¹ßÇàºÒ°¡)
2) ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4ÀÎ/1½Ç), 24ÀÏ Áᫎ ¹× ¼®½Ä, 25ÀÏ Á¶½Ä ¹× Áᫎ Æ÷ÇÔ
3) ¼¼±Ý°è»ê¼­ ¹ß±Þ (ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇϽŠºÐÀº »ç¾÷ÀÚµî·ÏÁõ ÷ºÎ ¿ä¸Á
4) ÇöÀåµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼­ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
5) ÀԱݰèÁ : ¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸
6) ÀԱݸ¶°¨ : 2019³â 10¿ù 18ÀÏ(±Ý), ÀÔ±Ý ½Ã ¼Ò¼Ó, ¼º¸í ±âÀÔ ¿ä¸Á
¹®ÀÇ ±âŸ ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031-702-9123 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. ±èÁذï
º°Ã· [°ø¹®] KSNS 36Â÷ ¿öÅ©¼¥ °³ÃÖ ¾È³»
º¸°Ç»ê¾÷ÁøÈï¿ø ±â¾÷È«º¸ ¸®Ç÷¿
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ ±â¼úºñÁî´Ï½º Çù·Â °øµ¿ ½ÉÆ÷Áö¿ò °èȹ¾È


¡á µî·Ï¾È³»

- »çÀüµî·Ï ¾È³»

µî·Ï±â°£ 2019³â 9¿ù 10ÀÏ (È­) ~ 10¿ù 16ÀÏ (¼ö)
µî·Ï¹æ¹ý - ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç >»çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.

- µî·Ïºñ <Áß¿ä°øÁö >Ä«µå°áÁ¦ °¡´É

µî·Ïºñ ±¸ºÐ »çÀüµî·Ï ÇöÀåµî·Ï
Á¤È¸¿ø 150,000¿ø 150,000¿ø
Çлýȸ¿ø 100,000¿ø 100,000¿ø
• »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4ÀÎ/1½Ç), 24ÀÏ Áᫎ ¹× ¼®½Ä, 25ÀÏ Á¶½Ä ¹× Áᫎ Æ÷ÇÔ
¼¼±Ý°è»ê¼­ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼­ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼­ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ

- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)

ÀԱݰèÁ ¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸
ÀԱݸ¶°¨ ~ 2019³â 10¿ù 18ÀÏ (±Ý) 18½Ã ±îÁö
ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
• ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼­ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ ÇÊ¿ä ÇÕ´Ï´Ù.
• ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
  TEL. 031-702-9123 / E-mail. ksns@nonclinical.or.kr, ±èÁذï


¡á ÇÁ·Î±×·¥ ¾È³»

  • ÀϽà : 2019³â 10¿ù 24ÀÏ(¸ñ) 12:00 ~ 25ÀÏ(±Ý) 15:00
  • Àå¼Ò : Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F)
  • ÁÖÁ¦ : ÇÏ´Ã, ¹Ù¶÷, º°, ±×¸®°í ½Å¾àÀÇ ²Þ

Day 1 10¿ù 24ÀÏ (¸ñ)
½Ã°£ ÇÁ·Î±×·¥
12:00~12:50 µî·Ï ¹× Á¡½Ä ½Ä»ç
12:50~13:00 °³È¸»ç (¿À¼¼¿õ ȸÀå)
13:00~13:10 Ãà»ç (½ÄǰÀǾàǰ¾ÈÀüÆò°¡¿øÀå À̵¿Èñ)
Session 1 Plenary talk
13:10~13:50 ÀÓ»óÀû °üÁ¡¿¡¼­ ¹Ù¶óº¸´Â ºñÀӻ󿬱¸ Àü·« (¿¬¼¼ÀÇ·á¿ø, ½ÉÀç¿ë)
Session 2 Platform
13:50~14:30 ¾Ï´Ü¹éÀ¯Àüü ºÐ¼®À» ÅëÇÑ ÀÌÇ༺¿¬±¸ ¹æÇâ (±¹¸³¾Ï¼¾ÅÍ, ¹ÚÁ¾¹è)
14:30~15:10 AI-powered drug discovery and development (GIST, ³²È£Á¤)
15:10~15:30 Booth exhibition & Coffee break
Session 3 Case study 1
15:30~16:10 BBT-877 ºñÀÓ»ó/ÀÓ»ó°³¹ß ¹× ¶óÀ̼¾½Ì (ºê¸´Áö¹ÙÀÌ¿À, ÀÌÁ¤±Ô)
16:10~16:50 ³­Ä¡¼º ¶Ç´Â °íÀ§Çè °¨¿°º´ ¿¹¹æ ¹é½ÅÀ¸·Î¼­ DNA¹é½ÅÀÇ ¿ªÇÒ ¹× ºñÀÓ»ó/ÀÓ»ó ¿¬±¸°³¹ß »ç·Ê (Áø¿ø»ý¸í°úÇÐ, Á¤¹®¼·)
16:50~17:40 DWN12088, A Novel First-In-Class PRS Inhibitor for the Treatment of Fibrotic Diseases
(´ë¿õÁ¦¾à, ¹ÚÁؼ®)
18:40~21:00 Dinner seminar(¿ì½Ã¾ÛÅØ/Å¥º£½ºÆ® ¹ÙÀÌ¿À) & Social networking

Day 2 10¿ù 25ÀÏ (±Ý)
½Ã°£ ÇÁ·Î±×·¥
07:00~09:30 ¾ÆÄ§ ½Ä»ç
Session 4 ¾àÈ¿ºÐ°ú µ¶¼ººÐ°ú ¾àµ¿ºÐ°ú
09:40~10:20 The current trend of allosteric SHP2 inhibitor in cancer
(SK¹ÙÀÌ¿ÀÆÊ, ±è³²ÈÆ)
US FDA SEND µµÀÔ¿¡ µû¸¥ ±¹³» ºñÀÓ»ó½ÃÇè±â°üÀÇ ´ëÀÀ°ú ³ª¾Æ°¥ ¹æÇâ
(KIT, Á¤ÁöÈÆ)
In vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters
(SOLVO, Beáta Marianna Kovács)
10:20~10:40 Booth exhibition & Coffee break
10:40~11:20 ±Û·Î¹ú ÀÓ»ó3»ó ÅëÁõ Ä¡·áÁ¦ Opiranserin °³¹ß »ç·Ê ¼Ò°³
(ºñº¸Á¸, ÀÌÇÑÁÖ)
ÀÓ»ó½ÃÇè°ËüºÐ¼®ÀÇ GLPÀû¿ë
(°Ç¾ç´ë, ȲÁø¾Æ)
Time-dependent Inhibitor¿Í Reactive Metabolite, ¹«¾ùÀÌ ´Ù¸¥°¡?
(LGÈ­ÇÐ, À̽ÂÇÐ)
11:20~11:40 Effect of intravitreal administration of ranibizumab inspontaneously dysmetabolic non-human primate
(Sichuan Primed Shines Biotech, Li Gong)
Challenges with Immunogenicity Assay Design to Support Gene Therapy Programs
(Charles River Lab., Jessica St. Charles)
Role and Consideration of Toxicokinetic study in preclinical study
(KIT, ÀÌÁ¾È­)
11:40~12:00 Novel strategies to optimize animal models of human nonalcoholic steatohepatitis for drug development
(Physiogenex, François Briand)
12:00~13:30 Luncheon seminar(DT & CRO) & Booth exhibition
Session 5 Case study 2
13:30~14:10 ÃֽŠFDA ½Å¾à½ÂÀÎ »ç·Ê ¼Ò°³ (SK¹ÙÀÌ¿ÀÆÊ, ¹ÚÁ¤½Å)
14:10~14:50 YH25724, a novel long-acting dual agonist for the treatment of nonalcoholic steatohepatitis (NASH) (À¯ÇѾçÇà, ±èÁØÈ¯)
14:50~15:00 Æóȸ»ç ¹× °æÇ° Ãß÷ (ºÎȸÀå, ½ÉÇöÁÖ)

¡Ý °øµ¿½ÉÆ÷Áö¿ò
Session 6 Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸/Çѱ¹º¸°Ç»ê¾÷ÁøÈï¿ø º¸°ÇÀÇ·á »êÇп¬º´ ±â¼ú-ºñÁî´Ï½º Çù·Â °øµ¿½ÉÆ÷Áö¿ò
Day 1 10¿ù 24ÀÏ (¸ñ)
½Ã°£ ÇÁ·Î±×·¥
~13:40 µî·Ï
13:40~14:00 ½Å°æÁ¤½ÅÁúȯ Ä¡·áÁ¦ ¾àÈ¿Æò°¡ Ç÷§Æû ±â¼ú (ÁÖ)´º·Îºñ½º
14:00~14:20 ´ë»çÈ¿¼Ò/¼ö¼Ûü ±â¹ÝÀÇ in vitro ADME ºÐ¼®±â¼ú ¹× ¾à¹°À¯ÀüÀÚ ºÐ¼®±â¼ú (ÁÖ)¿¡½ºÇǸ޵å
14:20~14:40 °íÇ÷¾Ð °³¼±À» À§ÇÑ »êÈ­Áú¼Ò(NO)ÃËÁø À½·á (ÁÖ)¹è·Á
14:40~15:00 Coffee break
15:00~18:00 º¸°ÇÀÇ·á TLO ¿¬±¸ÀÚ ¹× ±â¾÷ °£ 1:! ±â¼ú ºñÁî´Ï½ºÆÄÆ®³Ê¸µ ¿¬±¸ÀÚ ¹× À¯¸Á/Á¦¾à±â¾÷
* »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.

¡á ¿À½Ã´Â ±æ

ÁÖ¼Ò Á¦ÁÖÆ¯º°ÀÚÄ¡µµ ¼­±ÍÆ÷½Ã ¼º»êÀ¾ ¼·ÁöÄÚÁö·Î 107 Èִнº Á¦ÁÖ
ȨÆäÀÌÁö Èִнº Á¦ÁÖ ¾ÆÀÏ·£µå º¼·ë (¿À·»Áöµ¿ 2F) ÀÚ¼¼È÷ º¸±â


¡á ±³Åë Æí

¡Ý ±ÞÇà¹ö½º
  • 110-1 (¼Ò¿ä½Ã°£:69ºÐ) [°øÇ× ¡æ °í¼º¸® ÇÏÂ÷ ¡æ ¼º»êÆ÷Ç× ¡æ ¿©°´Å͹̳Î]
  • 110-2 (¼Ò¿ä½Ã°£:85ºÐ) [°øÇ× ¡æ °í¼º¸® ÇÏÂ÷ ¡æ ¼º»êÆ÷Ç× ¡æ ¿©°´Å͹̳Î]
  • °í¼º¸® ÇÏÂ÷ ÈÄ Åýà ÀÌ¿ë:°Å¸® 3.1 km / ¿ä±Ý 4õ¿ø ÀÌÇÏ
  • ±ÞÇà¹ö½º ž½ÂÀå:°øÇ× 1¹ø Ãⱸ ¾Õ

¡Ý °øÇ× ¹«·á ¼ÅƲ

• °øÇ× ¡æ Èִнº Á¦ÁÖ (10¿ù 24ÀÏ)
±¸ºÐ 1ȸÂ÷ Ãß°¡1* Ãß°¡2* Ãß°¡3* 2ȸÂ÷ Ãß°¡4* 3ȸÂ÷ 4ȸÂ÷ 5ȸÂ÷
Ãâ¹ß½Ã°£ 10:00 10:30 11:00 11:30 12:00 12:30 14:00 16:00 19:10
µµÂø½Ã°£ 11:10 11:40 12:10 12:40 13:10 13:40 15:10 17:10 20:20
ž½ÂÀå¼Ò Á¦ÁÖ°øÇ× C-Zone (9, 10, 11¹ø) ÁÖÂ÷Àå
* ¿öÅ©¼¥ Âü¼®ÀÚ¸¦ À§ÇÑ Ãß°¡ ¼ÅƲ Â÷·®

• Èִнº Á¦ÁÖ ¡æ °øÇ× (10¿ù 25ÀÏ)
±¸ºÐ 1ȸÂ÷ 2ȸÂ÷ 3ȸÂ÷ 4ȸÂ÷ Ãß°¡1~4* 5ȸÂ÷
Ãâ¹ß½Ã°£ - 10:30 12:30 14:30 15:00~16:00 17:30
µµÂø½Ã°£ - 11:40 12:40 15:40 16:10~17:10 19:00
ž½ÂÀå¼Ò ¿À·»Áöµ¿ Çö°ü ¾Õ
* ¿öÅ©¼¥ Âü¼®ÀÚ¸¦ À§ÇÑ Ãß°¡ ¼ÅƲ Â÷·®, ÇÁ·Î±×·¥ Á¾·á ÈÄ ¹Ù·Î ½ÂÂ÷Çϰí Ãâ¹ß ¿¹Á¤
** µµÂø½Ã°£Àº µµ·Î ±³Åë »óȲ¿¡ µû¶ó ´Ù¼Ò Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¾çÇØºÎʵ右´Ï´Ù.




List
°³ÀÎÁ¤º¸Ãë±Þ¹æÄ§
(ÁÖ)µå¸²ÆÄÆ®³Ê (»ç¾÷ÀÚµî·Ï¹øÈ£ : 320-88-00843, ´ëÇ¥ : ±è»ó¿ì)
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ (The Korean Society Nonclinical Study)
(¿ì)446-982 °æ±âµµ ¿ëÀνà ±âÈﱸ Èï´öÁß¾Ó·Î 120 U-TOWER 1411È£
Tel : 031-702-9123 , Fax : 031-213-9125, E-Mail : ksns@nonclinical.or.kr
Copyright & "The Korean Society Nonclinical Study". Website development and maintenance: "Expedition". All Rights Reserved.